
Amyloid neuropathies are important causes of progressive neuropathy and are increasingly treatable when recognized earlier. In this episode, Dr. Marcus Pinto reviews the major types of amyloid neuropathy, key diagnostic red flags, and the evolving treatment options for AL and hereditary ATTR amyloidosis. Learn how timely diagnosis can help prevent disease progression and improve patient outcomes.
In this episode, Gordon Smith, MD, FAAN, speaks with Marcus V. Pinto, MD, MS, author of the article "Amyloid Neuropathies" in the Continuum® October 2026 Peripheral Nerve and Motor Neuron Disorders issue.
Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia.
Dr. Pinto is an assistant professor of neurology and medical director of the Nerve Pathology Laboratory at Mayo Clinic in Rochester, Minnesota.
Additional Resources
Read the article: Amyloid Neuropathies
Subscribe to Continuum®: shop.lww.com/Continuum
Earn CME (available only to AAN members): continpub.com/AudioCME
Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud
More about the American Academy of Neurology: aan.com
Social Media
Host: @GordonSmithMD
Guest: @MarcusVPinto
Full episode transcript available here
Dr. Smith: One of the wonderful things about being a neurologist these days is the unbelievable therapeutic development, particularly for diseases that have been historically devastating for patients. I suspect many of you, like me, have found amyloidosis a sometimes confusing topic, but given the exciting therapeutic development for amyloid, it's a diagnosis that you really can't afford to miss if you're seeing patients with neuropathy. If you're interested in seeing order out of chaos and learning about amyloid in an organized way, and in particular, learning how to recognize patients who might benefit from these exciting new therapies, please keep listening.
Dr. Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.
Dr. Smith: This is Dr. Gordon Smith. Today, I've got a real pleasure. I get to interview Dr. Marcus Pinto about his article on amyloid neuropathies. This article appears in the October 2026 Continuum issue on peripheral nerve and motor neuron disorders. Marcus, welcome to the Continuum Audio Podcast, and maybe you can start by introducing yourself to our audience.
Dr. Pinto: Thank you, Dr. Smith. It's an honor for me to be here. So, my name is Marcus Pinto. I'm a peripheral nerve neurologist here at Mayo Clinic in Rochester.
Dr. Smith: Marcus, it's a great article, and you're obviously a leader in the neuropathy field. I don't know that our listeners know what they're in for. This is super exciting. I always think back to medical school, and we used to joke that if you fall asleep during rounds and you wake up, just yell "amyloid," because it's a complicated enough topic that can mimic so many different things. And what's I think particularly exciting now is therapeutic development is really amazing. So many great stories, and I know our listeners are going to be very excited about that. But I wonder if you might begin with just a simple question. What is amyloid?
Dr. Pinto: Yeah, so amyloid is an abnormal protein that misfolds in the blood and will deposit on tissues and causes usually mechanical or toxic damage to that organ. And as you said, it can affect the whole body. And it's very exciting now because the most common causes of amyloid neuropathy are treatable, which are AL amyloidosis and also hereditary ATTR amyloidosis. So, it's very exciting times for amyloid neuropathies.
Dr. Smith: We are all hearing about amyloid now in the context of Alzheimer's disease or amyloid angiopathy. Can you kind of talk to us a little bit about just the relationship between these? Are they distinct entities, or are there some relationships that we should be aware of?
Dr. Pinto: Yeah, I think that's very important to differentiate these disorders. So, whenever we talk about amyloidosis, you can have focal amyloidosis, which is Alzheimer's disease is a great example, or cerebro amyloid angiopathy. So, someone with CAA or someone with Alzheimer's disease, sometimes they occur together, they will only have amyloidosis in the brain. These are called focal amyloidosis. Can also, for example, happen in the eye sometimes and in other organs, and it's called focal
amyloidosis. So, the disorders that we are talking about, talking about amyloid neuropathy, you're talking about systemic amyloidosis. So, diseases that will affect not only one organ, usually multiple organs, including the peripheral nerves, sensory motor, and autonomic.
Dr. Smith: Are there focal neuropathic amyloid syndromes?
Dr. Pinto: Yes. Very rarely, one can have something called an amyloidoma affecting a peripheral nerve, a single peripheral nerve, or a plexus, brachial, lumbosacral. Some of these patients, they will have a monoclonal gammopathy, but some of them, around 50% of them, do not have a monoclonal gammopathy, and you only identify the type of amyloidosis after a biopsy and doing mass spectrometry of the nerve. And all the reported cases so far of amyloidoma affecting the nerve, which is again a very rare disorder, are caused by light chain or AL amyloidosis, that even though the note is a systemic disorder, very rarely can also be focal.
Dr. Smith: I think it's really helpful to have this framework of focal versus systemic amyloid, and I never really thought about Alzheimer's before as a focal amyloid syndrome. So, I think that's helpful in creating clarity in an area that has historically been confusing to a lot of us. There are a bunch of different forms of amyloid neuropathy. You've already mentioned light chain and hereditary amyloid neuropathy. What are the main forms that our listeners need to be familiar with?
Dr. Pinto: So, I usually list 4 major types of amyloid neuropathy. So, the hereditary TTR, immunoglobulin light chain or AL amyloidosis, gelsolin amyloidosis, and a fourth one, which is wild-type ATTR. So, transthyretin, the protein, when deposits on tissue as amyloid, can be caused by a genetic form. So, these patients will have a pathogenic variant in the TTR gene, and there are other patients who will not have any abnormal variant in the TTR gene. And when we also do mass spec of the amyloid protein, it's normal transthyretin without any confirmation or any amino acid change, and these cases are called wild-type amyloidosis. Wild-type amyloidosis is considered an aging disorder, so it usually happens in men when they are older than 70 years old. It's like a nine to one ratio, male to female, and occur mostly in the elderly population.
Dr. Smith: And wild-type typically causes cardiac manifestations, but we sometimes see neuropathy. Do you think that the neuropathies that we see in patients who have wild-type amyloid are amyloid-related, or do you think that they're just coincidental, just with aging?
Dr. Pinto: That's a common question we get from our cardiology colleagues. I like to compare wild-type ATTR amyloidosis with one type of hereditary TTR amyloidosis. So, whenever talking about hereditary TTR, there is a strong genotypic phenotypic correlation. Okay? So, some specific variants cause more cardiomyopathy than neuropathy and vice versa. Some other variants usually cause both. There is one type of hereditary TTR, a variant of Val122Ile, or in the new classification, p.Val142Ile, that they present very similar to wild-type amyloidosis. So, these patients, they may have a peripheral neuropathy, and there's always a question. So, is it caused by wild-type amyloidosis? Is it caused by Val122Ile amyloidosis? So, the framework that I usually do is check for the comorbidities. Is the patient diabetic, obese, metabolic syndrome? Does the patient have any other cause for neuropathy? Because usually most of these cases with wild-type ATTR or Val122Ile hereditary TTR with cardiomyopathy that have
neuropathy, the neuropathy is caused by another disorder, and it's not caused by the amyloid. However, rarely in clinic, we see patients who do have a progressive neuropathy, usually more of a slowly progressive neuropathy, and have wild-type TTR amyloidosis, and you can't find other cause for neuropathy. So, in these cases, and I have done that, that I have even have done nerve biopsies on these patients and even not finding the wild-type TTR amyloid in the nerve, that I've told the cardiologist, "Hey, I've done my homework here. I did not find any other cause of neuropathy." I've seen this patient after 6 months, one year, and this neuropathy is slowly progressing. It doesn't look like a hereditary neuropathy, like a CMT. Doesn't sound like idiopathic neuropathy because there are weakness, it's progressive. The idiopathic neuropathy usually when progresses very, very slowly. So that I have attributed the neuropathy to wild-type.
Dr. Smith: I think we probably should pivot here, Marcus, and spend most of our time talking about light chain and hereditary ATTR. But I think this is a topic that we come across all the time, at least where I practice. We take care of a large population of African Americans. As you know, the Val122Ile mutation is very common in that population, and we have to kind of take that fish off the hook and figure out. And there's obviously been a lot of therapeutic development in cardiac amyloid as well, and our listeners should definitely read your article to learn more about that. But let's pivot and talk about the light chain amyloid and hereditary amyloid, and what are the diagnostic clues? You just differentiated idiopathic neuropathy from the progressive neuropathy we occasionally see in wild-type amyloid, but what are the red flags for light chain or hereditary amyloid?
Dr. Pinto: Yeah, I think this is a great question. And usually I like to first, when we're talking about red flags for systemic amyloidosis, I like to kind of put them together and then we will differentiate them further later. So, I think whenever a patient has unexplained weight loss, unexplained heart failure, unexplained lower limb edema, they have a progressive neuropathy of some kind. And usually I call progressive neuropathy a neuropathy that the patient, for example, is a rapidly progressive neuropathy. The patient needs like a gait aid in less than 6 months. The patient has developed an ankle weakness in less than 6 months. This neuropathy is progressing rapidly. This is not diabetic neuropathy. This is not metabolic synesthesia neuropathy. These are usually major red flags for this disorder. Whenever you are doing your neuropathy workup, you will, based on the AAN recommendations, you will be checking a monoclonal gammopathy with usually ideally immunofixation with a SPEP in the blood. And always it's important to emphasize the importance of also checking the free light chains, which are usually forgotten. And the AAN guidelines only talk about SPEP and immunofixation. They do not include there the free light chains, and it's important because 50% of the AL amyloidosis cases, they are free light chain only, meaning SPEP immunofixation may be normal, and you're only going to diagnose the amyloidosis doing the free light chain in the blood. So, the red flags for amyloidosis, I think it's important to focus on the systemic aspects of the disorder. And whenever one is seeing a patient with peripheral neuropathy, it's very important to do a thorough review of systems. Ask about cardiac, renal, pulmonary, unexplained weight loss, fever. So, any neuropathy that has autonomic symptoms, that has cardiac features, that have unexplained weight loss, neurologists should be concerned about amyloidosis. And one thing that I try to emphasize in my manuscript is that patients with peripheral neuropathy- At diagnosis should be part of the neurologic examination, measuring the blood pressure in the supine position, so laying down, and also after one and two minutes of standing.
Because if this patient does have neurogenic orthostatic hypotension, so this patient has a major red flag for having an amyloid neuropathy, which again, is treatable and must not be missed.
Dr. Smith: Yeah, super helpful. Are there other aspects of the neuropathy itself? I just think back to what we were taught growing up, that amyloid is a small fiber neuropathy with autonomic failure, and that's what it looks like, right? Maybe you can respond to that, because you've emphasized weakness and weight loss, and there are variations between the typical phenotype we see in kind of non-endemic regions like the United States versus if we were in Porto, in Portugal, for instance. Can you speak to what our listeners should be on the lookout for amyloid neuropathy, particularly non-endemic regions?
Dr. Pinto: Yeah. In the United States, hereditary ATTR neuropathy can be tricky to diagnose. If you see a patient after the first few months of symptoms, they may look like a garden variety neuropathy. They may look like a diabetic or idiopathic neuropathy, especially in the beginning. And in the United States and other non-endemic regions of the world, patients with hereditary ATTR usually present as a late onset. They usually have mild autonomic features. They may have orthostatic hypotension on examination, but they may have no symptoms from it. It's usually a neuropathy affects the small and large fibers together, so a panmodal sensation loss. So, in several regions of the world, ATTR neuropathy presents in a non-specific way, not as a classic textbook amyloid neuropathy, which starts with small fiber involvement, severe autonomic symptoms, and is rapidly progressive. Whenever someone is seeing a patient with a progressive peripheral neuropathy, even if there are no other symptoms, there are no autonomic, there are no systemic, there is no weight loss, you should think about hereditary ATTR amyloidosis.
Dr. Smith: Before getting into how to diagnose and treat, which is really the fun stuff, what threshold do you have to biopsy or sequence a patient who has what seems like a garden variety neuropathy? There are a bunch of studies that have looked at this. What's the yield? How much of an atypical phenotype do you need to have before, right? Because now that we've got these exciting therapies, we really want to find these patients. You made a strong statement, you cannot afford to miss this, right? So, talk about when to test.
Dr. Pinto: Yeah. So, I think whenever a patient has rapidly progressive peripheral neuropathy, and I would define rapidly progressive, it's one thing rapidly progressive when you see the patient at diagnosis. Per history, sometimes not easy to define if it's a rapidly progressive or progressive neuropathy, and you may need to see the patient back, like in 6 months or so, 3 months or so. But at diagnosis, if you see a patient with less than 6 months of symptoms or less than one year of symptoms, I think we can say that, that already needs a gait age. They already have a foot drop. So, I think this is a major red flag. Other major red flag is if the patient has, again, neurogenic orthostatic hypotension examination, and you also do the supine and standing blood pressure, and you find that they have neurogenic OH, that is a major red flag. Another major red flag, I think it's systemic features, okay? And systemic features, I'm talking about unexplained hypertrophic cardiomyopathy. I'm talking about proteinuria, unexplained proteinuria, or they have unexplained weight loss of around more than 10 pounds within 6 months, or they have anosmia, or they have specific skin features for AL amyloidosis, like periorbital purpura, the raccoon eyes, if they have a macroglossia as well. So, these are, I think,
major red flags for the diagnosis of amyloid neuropathy. In these patients, I recommend off the bat doing either a fat aspirate or a skin biopsy, and also doing T-charge and sequencing.
Dr. Smith: What are the differences between light chain and hereditary amyloidosis? You mentioned earlier that we would get to that. Now seems like a good time to explore that topic.
Dr. Pinto: Yeah. So, I think AL amyloidosis is a more rapid progressive disease than TTR amyloidosis. There are studies showing that especially the AL amyloidosis have a worse survival than ATTR amyloidosis, and the neuropathy also may progress faster. So, the AL amyloidosis, they may have these classic skin features, periorbital purpura. They also may have macroglossia. They also may have easy bruising in the skin. They more commonly have proteinuria in the urine test. And you can only do like a urinalysis, for example, that can a lot of times, the urinalysis will estimate the amount of protein in the urine. And around 64% of them, 65 will have the like cardiomyopathy. So, AL amyloidosis, it's more of a systemic disease than ATTR. Patients are sicker, they look sicker, and usually progress faster. ATTR, as I mentioned previously, usually affects the heart and/or the nerve. In the US, the phenotype patients have, usually it's more of a mixed phenotype. So, in the US around only 10 or 20% of patients will have only nerve phenotype. So, partnering with your internal medicine colleagues and your cardiology colleagues is important because most of the patients with amyloid neuropathy in America will have also amyloid cardiomyopathy.
Dr. Smith: I really want to get to treatment, but one last question before we do so, and that is the need for a biopsy. Does every patient with amyloidosis need to have tissue confirmation? If so, why?
Dr. Pinto: Very important question, Gordon. It's part of the definition of AL amyloidosis to have amyloid tissue confirmation. This is in any part of the world. When you're talking about hereditary ATTR, this is trickier. And why? Hereditary TTR, as I said before, has genotypic-phenotypic correlation, and there is also a geographic variation of the disease. Because the same Val30Met mutation can present in Portugal and Brazil as a classic amyloid neuropathy, and in the United States, it can present as a garden variety neuropathy, as a progressive neuropathy without the typical small fiber predominant major autonomic dysfunction. So, in the United States, it's recommended that every single patient with hereditary TTR neuropathy should have tissue confirmation. And why? It's because the penetrance of the mutations in the US are estimated to be lower than the penetrance in endemic regions. So, whenever you have a positive tissue biopsy, you know for sure that that patient has hereditary amyloidosis. So, then you are
going to start the patient on a very expensive treatment, and so then it's important for you to be sure that they do have the disease and you're not going to be treating gene carrier.
Dr. Smith: Yeah, really important point. Let's get to the treatment because this is a super exciting area.
Dr. Pinto: So, the treatment of AL amyloidosis, so AL amyloidosis is a treatable disorder, and the treatment is driven by the hematology. So, you need to have a hematology on your speed dial if you are a neuropathy doctor. You may already have one. They are very important colleagues because when you're talking about AL
amyloidosis, you're talking about systemic chemotherapy, okay? So, one recent advance in the care for patients with AL amyloidosis is that in the past, autologous stem cell transplantation was considered 1st line therapy, but now with the daratumumab, which is a plasma cell depleting drug that has kind of changed the landscape of treatment, and the 1st line therapy is a combination of daratumumab, bortezomib, cyclophosphamide, and dexamethasone. And if the patient does not respond, doesn't achieve what they call very good partial response on this regimen, then they consider the patient for pomalidomide, stem cell transplantation, venetoclax, CAR T, and so forth. AL amyloidosis, the neurologist partner with the hematologist helping managing the pain, helping managing the orthostatic hypotension, but the hematologist will be the one driving therapy. When you go to hereditary TTR amyloidosis, it's a different story. So TTR is produced by the liver, and then the mutation, the change of conformation, deposit on tissues. Then the treatments that we have for hereditary TTR are they focus on the liver, on the production of UTR, or they will focus on the binding the TTR protein and stabilizing the protein, because the dissociation of the tetramer into monomer, it's very important in the amyloidogenesis of the disease. Here in United States, we have available for patients liver transplantation, we have the gene silencers, and the TTR stabilizers. Liver transplantation here in the United States is usually not an option because most patients here won't have the classic early onset V30Met phenotype, which are the patients who can benefit from liver transplantation. And also, it comes with a lot of morbidity, the liver transplantation procedure. So, we usually do not use liver transplantation here in the US anymore. The gene silencers, so we have now 3 available gene silencers here in the United States. These gene silencers, what they do, one type, they are antisense oligonucleotides. They go and they block the messenger RNA. Other ones are small interfering RNAs, which will lead to degradation of this messaging RNA, and they are very potent in reducing the TTR levels from 80 to around 90%. We have the ASO available called Eplontersen, and we have these small interfering RNAs available. We have an IV formulation, which called Patisiran, and subcutaneous formulation called Vutrisiran.
Dr. Smith: You know, Marcus, these drugs are super exciting, right? Like, I think Patisiran was the first ever approved small interfering RNA for any disease. There's a great deal of excitement about these, and they're clearly helpful for patients. The trials are unequivocal. I wonder, though, if you can talk to us about what this means in the real life of a patient, right? These are expensive drugs and a lot of health system cost. I mean, is there a big return on investment in these drugs for patients? Do we see people with dramatic changes in outcomes? Is it- A modest effect, and I know that this is just looking for kind of an average answer, but how much excitement is there regarding magnitude of benefit?
Dr. Pinto: Yeah, that's a very important point, Gordon, and you were right. Patisiran was the 1st multi-fRNA approved. The goal of the therapy is to stop progression. So, we do not see major gains in function, major improvement of symptoms. The goal here is to suppress TTR production and prevent further amyloid deposition. We are not removing amyloid from the nerve. We are not regenerating the nerves. So, it's very important to set up the expectation with the patient that these drugs are very expensive. The goal here is to stop progression.
Dr. Smith: And presumably extend life.
Dr. Pinto: Yes. We have had the longest follow-up was 5 years with patisiran, but based on the older studies with TTR stabilizer, as the gene silences are more potent, we'll most likely see great improvement in survival of these patients.
Dr. Smith: Right, and the therapeutic development is continuing as our listeners will learn when they read your article, which I really think is a must-read article, by the way. Marcus, this has been such a great conversation. I really do think this is a must-read article if you're taking care of patients with peripheral neuropathy. You definitely don't want to miss it. What a tour de force. I've really enjoyed this. I could keep talking for you for the next half hour, but I don't think we have that kind of time right now. Thank you so much for a super interesting and engaging conversation.
Dr. Pinto: My pleasure, Gordon.
Dr. Smith: Again, today I've been interviewing Dr. Marcus Pinto about his article on amyloid neuropathies. This article appears in the October 2026 Continuum issue on peripheral nerve and motor neuron disorders. Be sure to check out Continuum audio episodes from this and other issues, and thanks to your listeners for joining us today.
Dr. Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audiocme. Thank you for listening to Continuum Audio.
Mais episódios de "Continuum Audio"



Não percas um episódio de “Continuum Audio” e subscrevê-lo na aplicação GetPodcast.








